Dr. Michael J. Mcmanus

Radiology
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Memorial Sloan Kettering Cancer Center
1275 York Ave, 
New York, NY 

Overview

Michael Mcmanus is a Radiologist practicing medicine in New York, New York.

His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Ganglioneuroblastoma, and Desmoid Tumor.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 31 clinical trials. Dr. Mcmanus is currently accepting new patients.

Specialties

Radiology

Hospital Affiliations

Overlook Medical Center
Riverview Medical Center
White Plains Hospital Center
Hunterdon Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Memorial Sloan Kettering Cancer Center
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
View 9 Less Clinical Trials

2 Total Publications

Quality of life before and after treatment of cutaneous metastases with palliative radiotherapy.
Quality of life before and after treatment of cutaneous metastases with palliative radiotherapy.
Journal: Journal of the American Academy of Dermatology
Published: July 28, 2021
Similar Doctors
Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required
1233 York Ave Apt 8j, 
New York, NY 
 (0.4 miles away)
917-455-2730
Languages Spoken:
English

Henry Kwok is a Radiologist practicing medicine in New York, New York. Dr. Kwok is highly rated in 1 condition, according to our data. His clinical expertise encompasses Lump in the Abdomen.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required
Before you request

Mount Sinai Medical Center

1450 Madison Ave, 
New York, NY 
 (1.8 miles away)
212-241-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alejandro Berenstein is a Radiologist practicing medicine in New York, New York. Dr. Berenstein is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Vein of Galen Aneurysm, Arteriovenous Malformation, Cerebral Arteriovenous Malformation, Liver Embolization, and Stent Placement. Dr. Berenstein is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required
Before you request

North Shore University Hospital

300 Community Dr, 
Manhasset, NY 
 (13.3 miles away)
516-562-2244
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Athos Patsalides is a Radiologist practicing medicine in Manhasset, New York. Dr. Patsalides is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pseudotumor Cerebri Syndrome, Brain Aneurysm, Cavernous Sinus Thrombosis, Stent Placement, and Endovascular Embolization. Dr. Patsalides is currently accepting new patients.

Frequently Asked Questions about Dr. Michael J. Mcmanus

How do I make an appointment with Dr. Michael J. Mcmanus?

You can book an appointment with Dr. Michael J. Mcmanus by calling their office at 929-298-9468. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael J. Mcmanus a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael J. Mcmanus is classified as an Experienced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael J. Mcmanus specialize in?

While Dr. Michael J. Mcmanus is a Radiology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Ganglioneuroblastoma, and Desmoid Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiology.

Does Dr. Michael J. Mcmanus participate in research or clinical trials?

Yes. Dr. Michael J. Mcmanus has published 2 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Michael J. Mcmanus's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael J. Mcmanus accept my insurance?

Dr. Michael J. Mcmanus accepts most major insurance plans, including Medicaid. We recommend calling the office directly at 929-298-9468 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcmanus's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile